NSG-Ab0-DQ8-INS*VNTR (or NSG-Ab0-DQ8-INS*VNTR) mice are NOD.scid.Il2Rγcnull ("NSG") animals lacking murine MHC class II (Ab0), expressing a humanized HLA-DQ8 molecule linked to type 1 diabetes development and a human proinsulin class I variant (INS*VNTR; 26-63 tandem ACAGGGGTGTGGGG repeats) common to individuals with type 1 diabetes. These mice are useful for studying type 1 diabetes, autoimmunity and transplantation.
Dr. David Serreze, The Jackson Laboratory
Genetic Background | Generation |
---|---|
|
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Spontaneous | Prkdc | protein kinase, DNA activated, catalytic polypeptide |
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Null/Knockout) | Il2rg | interleukin 2 receptor, gamma chain |
Allele Type | Gene Symbol | Gene Name |
---|---|---|
Targeted (Null/Knockout) | H2-Ab1 | histocompatibility 2, class II antigen A, beta 1 |
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Type |
---|
Transgenic (Inserted expressed sequence, Humanized sequence) |
NSG-Ab0-DQ8-INS*VNTR (or NSG-Ab0-DQ8-INS*VNTR) mice are NOD.scid.Il2Rγcnull ("NSG"; Stock No. 005557) animals also lacking murine MHC class II (Ab0) that express the HLA-DQ8A transgene (Tg(HLA-DQA1,HLA-DQB1)1Dv) and the INS*VNTR transgene (Tg(INS*)172Dvs).
The following genotype(s) may be collectively referred to as NSG-Ab0-DQ8-INS*VNTR mice: females homozygous for scid, Ab0, Il2Rγcnull and HLA-DQ8A and hemizygous for the HLA-DQ8A transgene - and males homozygous for scid and Ab0, hemizygous for the X-linked Il2Rγcnull, homozygous for HLA-DQ8A and hemizygous for INS*VNTR.
The human insulin gene (INS) is translated into preproinsulin (the precursor of mature insulin), which is processed to proinsulin by removal of the signal peptide and then to mature biologically active insulin by removal of the C-peptide. In the INS promoter region, a variable number tandem repeat (VNTR) region consisting of a 14-15 bp consensus sequence is associated with three classes of alleles: there is a higher frequency of class I alleles with shorter repeat sequences in individuals with Type 1 diabetes, whereas individuals with longer class III alleles are relatively protected from Type 1 diabetes. The VNTR regulates transcription rates of insulin and its precursors. The INS*VNTR transgene derived from founder line 17-2 (172) expresses a human proinsulin class I variant (26-63 tandem ACAGGGGTGTGGGG repeats).
Therefore, the NSG-Ab0-DQ8-INS*VNTR mice may be expected to combine the NSG phenotype (Stock No. 005557) and murine MHC class II knockout phenotype, while expressing a humanized HLA-DQ8 molecule linked to Type 1 diabetes development (see Stock No. 026561) - and also expressing a class I variant human proinsulin (INS*VNTR) common to individuals with Type 1 diabetes.
When hemizygous for the INS*VNTR transgene derived from line 17-2 (172), both female and male NSG-Ab0-DQ8-INS*VNTR mice show high expression levels of human insulin and human C-peptide in both serum and pancreas.
Stock No. 005557: Although viable and fertile, homozygous NSG mice are immunodeficient: they have no mature T cells or B cells, lack functional natural killer (NK) cells, have reduced numbers of lymphocytes and myeloid dendritic cells, and are deficient in cytokine signaling.
Stock No. 026561: NSG-Ab0-DQ8 are viable and fertile. Ab0 homozygotes do not express murine major histocompatibility complex (MHC) class II. Human haematopoietic stem cell-engraftment in NSG-Ab0-DQ8 mice results in human insulin-specific Foxp3+ Treg-induction upon subimmunogenic vaccination with strong agonistic insulin mimetopes in vivo. These Tregs are stable and show increased expression of Treg signature genes while suppressing effector T cells.
Similar to other immunodeficient strains, maintaining NSG-Ab0-DQ8-INS*VNTR mice in high health status (specific pathogen-free) vivaria promotes overall colony health. If NSG-Ab0-DQ8-INS*VNTR animals are maintained in low health barrier rooms, the use of medicated water (e.g., sulfatrim/trimethoprim-sulfa or enrofloxacin/Baytril) is suggested to increase overall colony health.
View our
Resources for the NSG mouse model, including discussion forum, immunodeficient model comparison, and categorized, up-to-date references.
NSG-Ab0-DQ8-INS*VNTR (or NSG-Ab0-DQ8-INS*VNTR) mice are NOD.scid.Il2Rγcnull ("NSG") animals with the H2-Ab1tm1Doi knockout allele (Ab0),
the HLA-DQ8A transgene (Tg(HLA-DQA1,HLA-DQB1)1Dv)
and the INS*VNTR transgene (Tg(INS*)172Dvs). NSG-Ab0-DQ8-INS*VNTR mice harbor several mutations, as described below.
NSG mice are non-obese diabetic animals (NOD/ShiLtJ) harboring the spontaneous severe combined immunodeficiency mutation (Prkdcscid) on chromosome 16 and the Il2Rγcnull mutation on the X chromosome (Il2rgtm1Wjl created by Dr. Warren J. Leonard [NIH]). NSG mice are described and available from The Jackson Laboratory Repository as Stock No. 005557.
The "MHC class II knockout" allele (Ab0; H2-Ab1tm1Doi) on chromosome 17 was created by Drs. Diane Mathis and Christophe Benoist (while at INSERM, Strasbourg, France) - see allele description for Stock Nos. 004606 or 010966. Mice with this Ab0 mutation on the NOD genetic background were used to assemble Stock No. 026936.
To create the HLA-DQ8A transgene (Tg(HLA-DQA1,HLA-DQB1)1Dv), a 30 kbp DNA fragment containing the DQA*0301 gene [from cosmid H11A] and a 38 kbp DNA fragment containing the DQB*0302 gene [from cosmid X10A] were microinjected into (CBA/J x B10.M)F2 embryos. To establish germline transmission, founders were mated to the B10.M strain. Mice with the HLA-DQ8A transgene on the NOD genetic background were used to assemble Stock No. 026936.
The INS*VNTR transgene (Tg(INS*)172Dvs) was created by the Type 1 Diabetes Repository (Dr. David V. Serreze) at The Jackson Laboratory. A human insulin genomic sequence was obtained with 26-63 tandem ACAGGGGTGTGGGG repeats in its promoter region. The transgene was microinjected into NSG embryos (Stock No. 005557). Mice from founder line 17-2 (172) were established and then bred to NOD-congenic mice harboring the Ab0 mutation and the HLA-DQ8A transgene. The resulting NSG-Abo-DQ8-INS*VNTR mutant mice were established at The Jackson Laboratory Repository as Stock No. 026936.
The colony is maintained by breeding females homozygous for scid, homozygous for Ab0, homozygous for the X-linked Il2Rγcnull, homozygous for HLA-DQ8A and hemizygous or noncarrier for INS*VNTR with males that are homozygous for scid, homozygous for Ab0, hemizygous for the X-linked Il2Rγcnull, homozygous for HLA-DQ8A and noncarrier or hemizygous for INS*VNTR.
Expressed Gene | HLA-DQA1, major histocompatibility complex, class II, DQ alpha 1, human |
---|---|
Expressed Gene | HLA-DQB1, major histocompatibility complex, class II, DQ beta 1, human |
Site of Expression | |
Expressed Gene | INS, insulin, human |
Site of Expression | Expression of the transgene is found in all primary cilia of the inner ear sensory epithelium. |
Allele Name | severe combined immunodeficiency |
---|---|
Allele Type | Spontaneous |
Allele Synonym(s) | SCID |
Gene Symbol and Name | Prkdc, protein kinase, DNA activated, catalytic polypeptide |
Gene Synonym(s) | |
Site of Expression | T and B lymphocytes. |
Strain of Origin | C.BKa-Ighb/Icr |
Chromosome | 16 |
Molecular Note | A T-to-A transversion point mutation at a position corresponding to codon 4046 (codon 4095 in transcript ENSMUST00000023352.8) created a premature stop codon (p.Y4046*). |
Allele Name | targeted mutation 1, Warren J Leonard |
---|---|
Allele Type | Targeted (Null/Knockout) |
Allele Synonym(s) | [KO]gammac; CD132-; gammac-; gc-; Il2rgtm1Wjll; IL2Rgammanull |
Gene Symbol and Name | Il2rg, interleukin 2 receptor, gamma chain |
Gene Synonym(s) | |
Site of Expression | Primarily lymphoid cells. |
Strain of Origin | 129S4/SvJae |
Chromosome | X |
Molecular Note | A neomycin resistance cassette replaced part of exon 3 and all of exons 4 - 8 of the gene, resulting in the loss of most of the extracellular domain and all of the transmembrane and cytoplasmic domains of the protein. |
Mutations Made By | Dr. Warren Leonard, NHLBI, NIH |
Allele Name | targeted mutation 1, Christophe Benoist and Diane Mathis |
---|---|
Allele Type | Targeted (Null/Knockout) |
Allele Synonym(s) | A beta0; Abbeta-; AB0; Abeta-; Class II0; H2-Ab1tm1Dim; H2-Ab1tm1Doi; II0; MHC class II-; MHCII-; MHC-II-k.o. |
Gene Symbol and Name | H2-Ab1, histocompatibility 2, class II antigen A, beta 1 |
Gene Synonym(s) | |
Strain of Origin | 129S2/SvPas |
Chromosome | 17 |
Molecular Note | The second exon was disrupted by the insertion of a neomycin resistance gene. In addition, the ES cell line used was derived from the 129S2/SvPas strain, which carries a deletion in the promoter region of H2-Ea. Consequently, these MHC class II molecule-deficient mice lacked cell surface expression of both class II-A and class II-E MHC proteins. |
Mutations Made By | Christophe Benoist, Joslin Diabetes Center |
Allele Name | transgene insertion 1, Chella David |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | Abeta0.DQ8; DQ8; HLA-DQ8; HLA-DQ8 Tg; HLA-DQA1*0301/DQB1*0302; Tg(HLA-DQA1*301,HLA-DQB1*302)1Dv |
Gene Symbol and Name | Tg(HLA-DQA1,HLA-DQB1)1Dv, transgene insertion 1, Chella David |
Gene Synonym(s) | |
Promoter | HLA-DQA1, major histocompatibility complex, class II, DQ alpha 1, human |
Promoter | HLA-DQB1, major histocompatibility complex, class II, DQ beta 1, human |
Expressed Gene | HLA-DQA1, major histocompatibility complex, class II, DQ alpha 1, human |
Expressed Gene | HLA-DQB1, major histocompatibility complex, class II, DQ beta 1, human |
Strain of Origin | (CBA/J x B10.M-H2f)F2 |
Chromosome | UN |
General Note | Flow cytometric analysis of peripheral blood leukocytes (PBL) using a monoclonal antibody to HLA-DQ demonstrated that transgenic mice express the transgenes. 25-40% of the PBLs of mixed-background transgenic mice homozygous for the targeted MHC class II mutation H2-Ab1tm1Dim express the transgenes. Lymph nodes of such mice contain three-fold the levels of CD4+ CD44+ T-cells as do those of nontransgenic MHC class II-deficient mice, levels similar to those of class II-sufficient mice. Immunization of transgenic H2-Ab1tm1Dim homozygous mice with bovine collagen II results in a strong IgG antibody response to the immunogen, and 66% of these mice develop severe, persistent arthritis. (J:88296) |
Molecular Note | A 30-kb human genomic DNA fragment containing the entire HLA-DQA1*0301 gene and a promoter-truncated HLA-DQB1*0302 gene from cosmid H11A and a 38-kb DNA fragment containing the entire HLA-DQB1*0302 gene from cosmid X10A were coinjected. |
Mutations Made By | Chella David, Mayo Clinic |
Allele Name | transgene insertion 172, David V Serreze |
---|---|
Allele Type | Transgenic (Inserted expressed sequence, Humanized sequence) |
Allele Synonym(s) | INS*VNTR |
Gene Symbol and Name | Tg(INS*)172Dvs, transgene insertion 172, David V Serreze |
Gene Synonym(s) | |
Promoter | INS, insulin, human |
Expressed Gene | INS, insulin, human |
Site of Expression | Expression of the transgene is found in all primary cilia of the inner ear sensory epithelium. |
Strain of Origin | NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ |
Chromosome | UN |
Molecular Note | The INS*VNTR transgene (Tg(INS*)172Dvs) was created by the Type 1 Diabetes Repository (Dr. David V. Serreze) at The Jackson Laboratory. A human insulin genomic sequence was obtained with 26-63 tandem ACAGGGGTGTGGGG repeats in its promoter region. |
The NSG-Ab0-DQ8-INS*VNTR (or NSG-Ab0-DQ8-INS*VNTR) live colony is maintained by breeding females homozygous for scid (Prkdcscid), homozygous for Ab0 (H2-Ab1tm1Doi), homozygous for the X-linked Il2Rγcnull (Il2rgtm1Wjl), homozygous for HLA-DQ8A (Tg(HLA-DQA1,HLA-DQB1)1Dv) and hemizygous or noncarrier for INS*VNTR (Tg(INS*)172Dvs) with males that are homozygous for scid, homozygous for Ab0, hemizygous for the X-linked Il2Rγcnull, homozygous for HLA-DQ8A and noncarrier or hemizygous for INS*VNTR.
Homozygous NSG mice are immunodeficient. As such, and similar to other immunodeficient strains, maintenance in high health status (specific pathogen-free) vivaria promotes overall colony health. If homozygous NSG-Foxn1null animals are maintained in low health barrier rooms, the use of medicated water (e.g., sulfatrim/trimethoprim-sulfa or enrofloxacin/Baytril) is suggested to increase overall colony health. Also see additional NSG housing information.
Female Homozygous for Prkdcscid, Homozygous for H2-Ab1tm1Doi, Homozygous for Il2rgtm1Wjl, Homozygous for Tg(HLA-DQA1,HLA-DQB1)1Dv), Noncarrier for Tg(INS*)172Dvs X Male Homozygous for Prkdcscid, Homozygous for H2-Ab1tm1Doi, Hemizygous for Il2rgtm1Wjl, Homozygous for Tg(HLA-DQA1,HLA-DQB1)1Dv), Hemizygous for Tg(INS*)172Dv
When using the NSG-Abo-DQ8-INS*VNTR , NSG-Abo-DQ8-INS*VNTR mouse strain in a publication, please cite the originating article(s) and include JAX stock #026936 in your Materials and Methods section.
Facility Barrier Level Descriptions
Service/Product | Description | Price |
---|---|---|
Homozygous for Prkdc<scid>and H2-Ab1<tm1Doi>, Homozygous or Hemizygous for Il2rg<tm1Wjl>, Heterozygous or wildtype for Tg(HLA-DQA1,HLA-DQB1)1Dv Tg(INS*)172Dvs |
Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project. We do not guarantee breeding performance and therefore suggest that investigators order more than one breeding pair to avoid delays in their research.
What information were you hoping to find through your search?
How easy was it to find what you were looking for?
We may wish to follow up with you. Enter your email if you are happy for us to connect and reachout to you with more questions.
Please Enter a Valid Email Address
Thank you for sharing your feedback! We are working on improving the JAX Mice search. Come back soon for exciting changes.